• Tropifexor (LJN452): A Translational FXR Strategy

  2026-09-04

  Tropifexor (LJN452) offers a precision pharmacology approach for connecting FXR activation with bile acid biology, metabolic disease research, and intestinal epithelial barrier function research. This thought-leadership guide shows how to position the compound within translational workflows, interpret liver and gut endpoints, and avoid overextending preclinical evidence.

• UTP Solution (100 mM): Reliable RNA Workflows

  2026-09-04

  Learn how UTP Solution (100 mM), SKU K1048, can reduce controllable variability in in vitro transcription, RNA amplification, and siRNA synthesis workflows that support cell-based research. This scenario-driven guide separates documented product specifications from application-level validation and connects nucleotide quality with interpretation of complex gene-expression assays.

• From Immune Rejuvenation to mRNA Strategy

  2026-09-03

  A translational framework linking immune-aging biology in Alzheimer’s disease models with selective, reproducible mRNA workflows using Oligo (dT) 25 Beads.

• Risedronate Sodium: From Mechanism to Assay

  2026-09-02

  Risedronate Sodium is more than an FPP synthase inhibitor: it is a translational probe linking osteoclast biology, formulation science, and clinically meaningful bone endpoints. This guide converts the RISOTTO trial into practical decisions for bone and pulmonary research assays.

• Cediranib (AZD2171) for Angiogenesis Assays

  2026-09-02

  Cediranib (AZD2171) combines sub-nanomolar VEGFR-2 activity with a workflow-friendly mechanism for dissecting angiogenesis, endothelial signaling, and tumor-cell responses. Pairing phospho-Akt measurements with separate proliferation and death assays prevents misleading conclusions from a single viability endpoint.

• AZD1480 Maps Tumor-Intrinsic STAT3 Signaling

  2026-09-01

  AZD1480 is a potent JAK2 inhibitor for resolving how inflammatory and immune signals sustain tumor-cell survival. This article presents a signal-provenance framework that connects pathway inhibition with compartment-aware cancer assays.

• Cabazitaxel (XRP6258): Resistant Model Guide

  2026-09-01

  Cabazitaxel (XRP6258, SKU B2157) is a semi-synthetic taxane derivative for studying microtubule-dependent growth inhibition, including P-glycoprotein-expressing and taxane-resistant cancer models. It is suitable for DMSO- or ethanol-based workflows but is insoluble in water, and prepared solutions should be used promptly rather than stored long term.

• Reactive Oxygen Species Assay Kit for Fibrosis

  2026-08-31

  Learn how DHE-based superoxide measurement can strengthen pulmonary fibrosis and mitophagy studies. This practical workflow combines plate-ready ROS detection with controls, normalization, and troubleshooting strategies for more interpretable oxidative stress data.

• Zosuquidar: A Transporter-Aware MDR Research Guide

  2026-08-31

  Zosuquidar (LY335979) is a selective P-glycoprotein modulator for dissecting chemotherapy efflux and multidrug resistance. This guide connects MDR assay design with pharmacokinetic lessons from a 2025 transporter study, helping researchers interpret sensitization data without overextending the evidence.

• Triterpene Prodrug for Targeted OSCC Chemotherapy

  2026-08-30

  This 2024 ACS Applied Materials & Interfaces study reports a carrier-free prodrug assembled from glycyrrhetinic acid and ginsenoside Rh2 for oral squamous cell carcinoma. A thioketal linker enables ROS-triggered release, while glycyrrhetinic acid amplifies oxidative stress and supports cooperative apoptosis with Rh2, providing a preclinical framework for self-assembled natural-product chemotherapy.

• Protease and Phosphatase Inhibitor Cocktail Guide

  2026-08-29

  This EDTA-free 100X cocktail helps limit proteolysis and dephosphorylation during extraction or lysis of cells and tissues, supporting analysis of protein abundance and phosphorylation states. It is intended for sample-preparation workflows, not direct treatment of living systems, and its working concentration and downstream compatibility should be validated for each matrix and assay.

• HyperScript First-Strand cDNA Synthesis Kit Workflow

  2026-08-28

  Build more reliable gene-expression workflows for structured RNA, long transcripts, and low-abundance targets with flexible primer selection and thermally stable reverse transcription. This practical guide applies the kit to miR-122-5p/PKM2 research while separating robust mRNA cDNA synthesis from specialized microRNA assay requirements.

• Clathrin-Mediated Entry of Grass Carp Reovirus

  2026-08-28

  Wang et al. used pharmacological inhibitors, transmission electron microscopy, and real-time quantitative PCR to show that genotype III grass carp reovirus enters CIK cells through clathrin-mediated, dynamin-dependent, and endosomal pH-dependent pathways. The lack of inhibition by Latrunculin B distinguishes this entry route from mechanisms that require detectable actin cytoskeleton disruption, while highlighting the need to interpret inhibitor panels as pathway evidence rather than standalone proof.

• TET2 Metabolite Binding: A Practical Validation Protocol

  2026-08-27

  This protocol establishes an integrated workflow for validating metabolite binding to human TET2 and determining whether those interactions activate or inhibit its dioxygenase activity. By combining tag-free TET2CD purification, flow cytometry-based 5hmC detection, and saturation transfer difference NMR, the study provides a practical framework for connecting metabolic state with epigenetic regulation.

• Caspase-8 Fluorometric Assay Kit Workflow

  2026-08-27

  Translate treatment-induced cell death into quantitative IETD-dependent fluorescence with a rapid, plate-based workflow. This guide shows how to apply the Caspase-8 Fluorometric Assay Kit to chemotherapy–hyperthermia studies, apoptosis assays, drug screening, and neurodegenerative disease models while avoiding common interpretation and optimization errors.

8670 records 7/578 page Previous Next First page 上5页 678910 下5页 Last page